Public Companies
Reunion Neuroscience Exec Steps Down as Director
Psychedelic drug maker Reunion Neuroscience (Nasdaq: REUN), formerly known as Field Trip Health, announced that Ronan Levy has stepped down from the board…
Psychedelic drug maker Reunion Neuroscience (Nasdaq: REUN), formerly known as Field Trip Health, announced that Ronan Levy has stepped down from the board and resigned his post as director.
Levy co-founded Field Trip Health.
The company’s corporate secretary and general counsel, Paula Amy Hewitt, also resigned.
“The company wishes both Ronan and Paula much success in their future endeavors and greatly appreciates the contributions that they made to support Reunion as it transitioned to a stand-alone entity,” a spokesperson told Green Market Report.
The news follows Reunion’s recent tapping of Greg Mayes as president and CEO. Mayes has been poised to replace Levy since the Sept. 28 announcement.
A company spokesperson said that Hewitt served Reunion as corporate secretary, but “was not employed by the company.”
“As such, Reunion needed to align its board support with an existing employee,” the spokesperson added.
CFO Donna Wong will fill Hewitt’s post as legal advisor.
The post Reunion Neuroscience Exec Steps Down as Director appeared first on Green Market Report.
psychedelic nasdaq field trip health field trip
-
Psychedelics1 week agoCybin Announces Grant of Additional U.S. Patent in Support of its CYB003 Breakthrough Therapy Program for Major Depressive Disorder
-
Law & Regulation1 week agoGoing concern warnings cloud Xtacy Therapeutics’ shrunk losses
-
Psilocybin1 week agoAre Shrooms Legal in Oregon: Full Guide
-
Psychedelics1 week agoOptimi Health Achieves Milestone: Completes In-House Production of MDMA Active Pharmaceutical Ingredient (API)
-
Psychedelics1 week agoAtai Life Sciences Announces the Publication of Beckley Psytech’s Phase 1 Study of BPL-003 in the Journal of Psychopharmacology
-
Psychedelics1 week agoPsyence Group’s NASDAQ Listed Associate, Psyence Biomedical Partners with Fluence and iNGENū CRO to Train Research Therapists for Phase IIb Psilocybin Trial
-
Law & Regulation1 week agoClearmind signs agreement with Hebrew University for psychedelic compound rights
-
Psychedelics1 week agoRevive Therapeutics Announces FDA Acceptance of Meeting Request for Long COVID Diagnostic Product